Pilot trial of a patient-specific cutaneous electrostimulation device (MC5-A Calmare®) for chemotherapy-induced peripheral neuropathy.
BACKGROUND
Chemotherapy-induced peripheral neuropathy (CIPN) is a major dose-limiting and persistent consequence of numerous classes of antineoplastic agents, affecting up to 30%-40% of patients. To date, there is no effective prevention or therapy. An evolving hypothesis for reducing CIPN pain involves direct nerve stimulation to reduce the pain impulse.


OBJECTIVE
To evaluate the impact on CIPN associated with the MC5-A Calmare® therapy device.


METHODS
The MC5-A Calmare® therapy device is designed to generate a patient-specific cutaneous electrostimulation to reduce the abnormal pain intensity. Sixteen patients from one center received one-hour interventions daily over 10 working days.


RESULTS
Of 18 patients, 16 were evaluable. The mean age of the patients was 58.6 years-four men and 14 women-and the duration of CIPN was three months to eight years. The most common drugs were taxanes, platinums, and bortezomib (Velcade, Millenium Pharmaceuticals, Cambridge MA). At the end of the study (Day 10), a 20% reduction in numeric pain scores was achieved in 15 of 16 patients. The pain score fell 59% from 5.81±1.11 before treatment to 2.38±1.82 at the end of 10 days (P<0.0001 by paired t-test). A daily treatment benefit was seen with a strong statistically significant difference between the pre- and post-daily pain scores (P<0.001). Four patients had their CIPN reduced to zero. A repeated-measures analysis using the scores from all 10 days confirmed these results. No toxicity was seen. Some responses have been durable without maintenance.


CONCLUSIONS
Patient-specific cutaneous electrostimulation with the MC5-A Calmare® device appears to dramatically reduce pain in refractory CIPN patients with no toxicity. Further studies are underway to define the benefit, mechanisms of action, and optimal schedule.
Smith
Thomas J
TJ
Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia, USA. tsmith5@mcvh-vcu.edu
Coyne
Patrick J
PJ
Parker
Gwendolyn L
GL
Dodson
Patricia
P
Ramakrishnan
Viswanathan
V
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001897:Boronic Acids; D000069286:Bortezomib; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010147:Pain Measurement; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced / Q000628:therapy*; D010865:Pilot Projects; D011719:Pyrazines; D043823:Taxoids / Q000009:adverse effects; D004561:Transcutaneous Electric Nerve Stimulation; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D043823:Taxoids; D000069286:Bortezomib
Anesth Analg. 2002 Mar;94(3):694-700; table of contents
11867400
J Clin Oncol. 1998 Nov;16(11):3662-73
9817289
Epilepsia. 1990;31 Suppl 2:S27-32
2226363
Cochrane Database Syst Rev. 2004;(3):CD003783
15266501
Cochrane Database Syst Rev. 2008 Jul 16;(3):CD006276
18646140
J Clin Oncol. 2002 Oct 1;20(19):4040-9
12351602
Pain. 2002 Jul;98(1-2):195-203
12098632
Clin J Oncol Nurs. 2007 Dec;11(6):901-13
18063548
Eur J Cancer. 2008 Jul;44(11):1507-15
18571399
Curr Opin Neurol. 2007 Dec;20(6):719-25
17992096
Cancer. 2008 Jun 15;112(12):2802-8
18428211
J Pain Symptom Manage. 2009 Aug;38(2 Suppl):S28-38
19671469
JOP. 2003 Jan;4(1):1-10
12555009
J Peripher Nerv Syst. 2008 Mar;13(1):27-46
18346229
Eur J Neurol. 2006 Nov;13(11):1153-69
17038030
Oncologist. 2009 May;14(5):448-55
19411315
Eur J Cancer. 2005 May;41(8):1135-9
15911236
Acupunct Med. 2006 Jun;24(2):87-91
16783284
JAMA. 1999 Mar 3;281(9):818-23
10071003
Expert Rev Med Devices. 2007 Mar;4(2):201-14
17359225
J Pain. 2010 Apr;11(4):351-9
19853518
Minerva Anestesiol. 2005 Jul-Aug;71(7-8):479-82
16012423
J Pain Symptom Manage. 2008 Jan;35(1):31-9
17980550
Eur J Pain. 2005 Aug;9(4):363-73
15979016
J Clin Oncol. 2014 Apr 1;32(10):997-1005
24297951
Cancer. 2007 Nov 1;110(9):2110-8
17853395